DR SARA HURVITZ APPOINTED TO SCIENTIFIC ADVISORY BOARD

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Sara Hurvitz MD to its Scientific Advisory Board (SAB).

Dr Hurvitz is a Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Medical Director of Jonsson Comprehensive Cancer Center’s Clinical Research Unit at UCLA, co-director of the Santa Monica-UCLA Outpatient Oncology Practice, and director of the Breast Oncology Program at UCLA’s Division of Hematology-Oncology.

Dr Hurvitz specialises in breast cancer treatment and is involved in designing, implementing, and leading clinical trials to test new targeted therapies. This includes studies of the gene expression patterns in various breast cancer populations and evaluating these patterns to detect new subtypes of breast cancer that novel therapies may more accurately target.

Dr Hurvitz maintains a robust clinical and translational research portfolio and has won numerous awards, including the Marine Levine Memorial Breast Cancer Research Award from 2008 through 2015.

She is also a member of the American Society of Clinical Oncology and the American Association of Cancer Research and is a fellow of the American College of Physicians.

“We are thrilled to have Dr Hurvitz join our highly experienced Scientific Advisory Board. Her wealth of expertise and thought leadership in cancer treatment will prove invaluable as we continue the development of our radiopharmaceutical products,” said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics.”

Dr Hurvitz joins Professor Eric Aboagye, Dr Johannes Notni, Dr Hong Hoi Ting and Dr David Ulmert on the SAB chaired by Radiopharm’s Chief Medical Officer Professor David Mozley.

Register Interest